Casdin Capital, LLC Adverum Biotechnologies, Inc. Transaction History

Casdin Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $7.43 Million - $23.4 Million	-2,211,622 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $13.3 Million - $20.7 Million	-1,438,378 Reduced 39.41%	2,211,622 $21.8 Million
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $8.86 Million - $12.8 Million	900,000 Added 32.73%	3,650,000 $39.6 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $9.12 Million - $19.2 Million	885,000 Added 47.45%	2,750,000 $28.3 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $6.31 Million - $19 Million	740,000 Added 65.78%	1,865,000 $38.9 Million
Q1 2020 May 15, 2020	BUY	$7.98 - $16.32 $8.98 Million - $18.4 Million	1,125,000 New	1,125,000 $11 Million
Q2 2018 Aug 14, 2018	SELL	$5.3 - $6.9 $1.59 Million - $2.07 Million	-300,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $1.1 Million - $2.39 Million	300,000 New	300,000 $1.74 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $478M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.